Mohlopheni is Faculty member at AHRI and an Associate Professor at UCL. His laboratory’s primary research interest is on immunopathogenesis of Tuberculosis, with an aim of developing host-directed therapies targeting lung inflammation. His other interests are in understanding strategies utilized by mycobacteria to survive the immune system. Work in his lab is funded by SAMRC, Wellcome Trust and Bill and Melinda Gates Foundation. In addition to his current positions at UCL and AHRI, Marakalala is also a Visiting Scientist at Harvard TH Chan School of Public Health, and he maintains an affiliation with UCT as an Honorary Research Associate.